Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Oblimersen in Untreated Follicular Lymphoma
NCT00301795Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Nov 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oblimersen in follicular lymphoma (FL), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 12 months. Started Mar 2006; status: terminated.
02
Drugs
oblimersen
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00301795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00301795.